Evaxion Biotech Yönetim

Yönetim kriter kontrolleri 3/4

Evaxion Biotech CEO'su Christian Kanstrup, Sep2023 tarihinde atandı, in görev süresi 1.17 yıldır. in toplam yıllık tazminatı $ 373.00K olup, şirket hissesi ve opsiyonları dahil olmak üzere 31.1% maaş ve 68.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.32% ine doğrudan sahiptir ve bu hisseler $ 109.56K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.2 yıl ve 3.8 yıldır.

Anahtar bilgiler

Christian Kanstrup

İcra Kurulu Başkanı

US$373.0k

Toplam tazminat

CEO maaş yüzdesi	31.1%
CEO görev süresi	1.2yrs
CEO sahipliği	1.3%
Yönetim ortalama görev süresi	2.2yrs
Yönetim Kurulu ortalama görev süresi	3.8yrs

Son yönetim güncellemeleri

Recent updates

Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration

Mar 31

Evaxion Biotech names Per Norlén as CEO

Oct 05

Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer

Sep 21

Evaxion Biotech posts preclinical proof of concept data for AI-powered vaccine platform

Jun 03

CEO Tazminat Analizi

Christian Kanstrup'un ücretlendirmesi Evaxion Biotech'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$11m
Jun 30 2024	n/a	n/a	-US$15m
Mar 31 2024	n/a	n/a	-US$15m
Dec 31 2023	US$373k	US$116k	-US$22m

Tazminat ve Piyasa: Christian 'nin toplam tazminatı ($USD 373.00K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 647.72K ).

Tazminat ve Kazançlar: Christian şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Christian Kanstrup (52 yo)

1.2yrs

Görev süresi

US$373,000

Tazminat

Mr. Christian Kanstrup, MSc, serves as Chief Executive Officer of Evaxion Biotech A/S since September 01, 2023. He joined Evaxion Biotech A/S on September 01, 2023. He previously served as Executive Vice P...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christian Kanstrup	Chief Executive Officer	1.2yrs	US$373.00k	1.32% $ 109.6k
Andreas Mattsson	Co-Founder and Chief AI & Culture Officer	16.8yrs	US$246.00k	7.68% $ 638.6k
Birgitte Rono	Chief Scientific Officer	3.2yrs	US$269.00k	0.066% $ 5.5k
Thomas Schmidt	Chief Financial Officer	no data	Veri yok	Veri yok

2.2yrs

Ortalama Görev Süresi

50yo

Ortalama Yaş

Deneyimli Yönetim: EVAX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Rajeev Surati	Member of Advisory Board	no data	Veri yok	Veri yok
Robert Palay	Member of Advisory Board	no data	Veri yok	Veri yok
Jeffrey Weber	Member of Advisory Board	no data	Veri yok	Veri yok
Soren Brunak	Member of Advisory Board	no data	Veri yok	Veri yok
Michael Washabaugh	Member of Advisory Board	no data	Veri yok	Veri yok
Thomas Wylonis	Member of Advisory Board	no data	Veri yok	Veri yok
Lars Holtug	Independent Director	3.5yrs	US$64.00k	0.13% $ 11.0k
Anthony Purcell	Member of Advisory Board	no data	Veri yok	Veri yok
Andrew Webber	Member of Advisory Board	no data	Veri yok	Veri yok
Marianne Sogaard	Independent Chairwoman of the Board	4yrs	US$193.00k	1.46% $ 121.7k
Roberto Pineda	Independent Director	6.8yrs	US$68.00k	0.72% $ 59.9k
Lars Wegner	Director	less than a year	US$407.00k	0.066% $ 5.5k

3.8yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: EVAX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).

Evaxion Biotech Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Evaxion Biotech A/S, Annual General Meeting, Apr 16, 2024

Evaxion Biotech A/S Appoints Christian Kanstrup as Chief Executive Officer

Evaxion Biotech A/S, Annual General Meeting, May 24, 2023

Evaxion Biotech A/S Welcomes Per Norlén as New CEO

Evaxion Biotech A/S Announces Executive Management Changes

Evaxion Biotech A/S Approves Election of Niels Iversen Møller as New Member of the Board of Directors

Recent updates

Evaxion Biotech A/S has filed a Follow-on Equity Offering in the amount of $12.5 million.

Evaxion Announces Positive Preclinical Data for Cytomegalovirus (CMV) Vaccine Program EVX-V1

Evaxion Update on Nasdaq Notification Regarding Minimum Stockholders’ Equity Requirement

Evaxion Biotech A/S to Report Q3, 2024 Results on Oct 31, 2024

Evaxion Biotech A/S Announces Strong Validation of Ai-Immunology Platform in Multiple Clinical Trials

Evaxion Biotech A/S Continues to Grows Clinical Evidence for the Steady Improvement of Its Ai-Immunology Platform

Evaxion Biotech A/S Reports Convincing One-Year Data from Phase 2 Trial on AI-Designed Personalized Cancer Vaccine EVX-01

Evaxion Biotech A/S Reports 69% Overall Response Rate in its Phase 2 Trial on Lead Cancer Vaccine Candidate EVX-01

Consensus revenue estimates increase by 331%

Evaxion Biotech A/S to Report Q2, 2024 Results on Aug 14, 2024

Evaxion Biotech A/S Announces Publication of Data from Its Phase 1 Dose Escalation Study of Its Lead Personalized Cancer Vaccine, EVX-01

Consensus revenue estimates decrease by 97%, EPS upgraded

Consensus revenue estimates decrease by 24%, EPS upgraded

New major risk - Financial position

Evaxion Biotech A/S to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024

Evaxion Announces Phase 2 Clinical Trial Update

Evaxion and Undisclosed Collaborator Announce Encouraging Results for Evx-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Consensus revenue estimates increase by 33%, EPS downgraded

Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration

Evaxion Biotech A/S, Annual General Meeting, Apr 16, 2024

Forecast to breakeven in 2025

Evaxion Biotech A/S has completed a Follow-on Equity Offering in the amount of $15 million.

New major risk - Negative shareholders equity

Evaxion Biotech A/S to Develop Tailored Novel Cancer Vaccines Based Upon A New Untapped Source of Ai-Discovered Targets

Evaxion Biotech A/S announced that it expects to receive $5.291433 million in funding from Merck Global Health Innovation Fund, LLC

Evaxion Biotech A/S announced that it expects to receive $5.291433 million in funding from Merck Global Health Innovation Fund, LLC

Evaxion Biotech A/S Announces Encouraging Initial Phase 2 Clinical Data on its Personalised Cancer Vaccine EVX-01

New and Exciting Clinical Data on Evaxion's Ai-Immunology™?-Based Personalized Cancer Vaccines to Be Presented

Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Evaxion Biotech A/S Expands Preclinical Bacterial Vaccine Pipeline in Collaboration with Leading Pharmaceutical Company

Evaxion Biotech A/S Announces New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development

Evaxion Biotech A/S Appoints Christian Kanstrup as Chief Executive Officer

Evaxion Biotech A/S announced that it expects to receive $20 million in funding from Negma Group Investment Ltd

Evaxion Biotech A/S Plans to Announce the Interim Results of the Clinical Phase 2 Study with EVX-01 in Patients with Metastatic Melanoma in Fourth Quarter 2023

Evaxion Unveils Genetic Adjuvant Technology to Boost Vaccines

Forecast to breakeven in 2024

Evaxion Unveils Proprietary Genetic Aduvant Technology to Boost the Effect of Dna and Mrna Vaccines

Evaxion Biotech A/S, Annual General Meeting, May 24, 2023

Evaxion Biotech A/S and Pantherna Therapeutics GmbH Announce Promising Preclinical mRNA Vaccine Data

Evaxion Receives FDA Fast-Track Designation for Personalized Cancer Immunotherapy

Evaxion Receives Phase IIb Go-Ahead from FDA

Evaxion Biotech A/S Receives Approval from FDA to Proceed with the Clinical Phase 2B Study for Evx-01

Evaxion Biotech Reaches an Important Milestone When Enrolled Its First Patient in Perth, Australia in the Company's Global Phase 2B Clinical Trial of EVX-01

Evaxion Biotech A/S Announces Promising Results from Phase 1/2a Clinical Trial of Personalized DNA Cancer Immunotherapy EVX-02

Price target decreased to US$14.67

Evaxion Biotech A/S Welcomes Per Norlén as New CEO

Evaxion Biotech names Per Norlén as CEO

Evaxion Biotech A/S Enrols First Patient in Phase Iib Melanoma Study

Evaxion Biotech A/S Enrolls First Patient in the Global Phase 2B Clinical Trial of EVX-01

Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer

Forecast to breakeven in 2024

Evaxion Biotech ADS GAAP EPS of -$0.20 beats by $0.10

Evaxion Biotech A/S Announces Executive Management Changes

Evaxion Biotech announces new CEO as Lars Wegner resigns

Evaxion Biotech A/S Announces Gonorrhea as Second Bacterial Product Target

Evaxion Biotech Expands its EVX-03 DNA Vaccine Program into Non-Small Cell Lung Cancer

Evaxion Biotech A/S announced that it expects to receive $40 million in funding from Lincoln Park Capital, LLC

Evaxion Biotech A/S Approves Election of Niels Iversen Møller as New Member of the Board of Directors

Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase 1/2A Clinical Trial for EVX-02

Evaxion Biotech A/S, Annual General Meeting, May 03, 2022

Evaxion Biotech A/S Announces Executive Changes

Evaxion Biotech A/S Completes Recruitment for Phase 1/2a Clinical Trial for EVX-02

Evaxion Biotech Announces Publication of Clinical Data of EVX-01 Heading into Phase 2b in Collaboration with Merck

Evaxion Biotech Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in Combination with KEYTRUDA® for Treatment of Melanoma

Is Evaxion Biotech (NASDAQ:EVAX) In A Good Position To Invest In Growth?

We're Hopeful That Evaxion Biotech (NASDAQ:EVAX) Will Use Its Cash Wisely

Evaxion Biotech Reports Preclinical Proof of Concept Data for Evaxion’s AI-powered Vaccine Platform RAVEN for the Design of a Next Generation SARS-CoV-2 Vaccine

Independent Director Helen Boudreau has left the company

Evaxion Biotech posts preclinical proof of concept data for AI-powered vaccine platform